Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
Rhea-AI Summary
Akebia Therapeutics (NASDAQ: AKBA) announced that CEO John P. Butler, CFO/Chief Business Officer Erik Ostrowski, and CMO Dr. Steven Burke will hold one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on April 14, 2026 in New York.
No company presentations are planned; management will discuss commercial products, and data and information from Akebia’s recent R&D Day showcasing its clinical-stage kidney disease pipeline.
Positive
- None.
Negative
- None.
News Market Reaction – AKBA
In the Apr 7 session, AKBA gained 4.55%, reflecting a moderate positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2026-04-01 | Board change | Positive | -2.1% | New director Philip Vickers appointed while another director retired. |
| 2026-03-19 | R&D day announcement | Neutral | +0.0% | Scheduled virtual R&D Day to review kidney disease pipeline. |
| 2026-03-03 | Conference participation | Neutral | -3.2% | Management fireside chat at Leerink Partners healthcare conference. |
| 2026-03-02 | Inducement grants | Neutral | -3.2% | Stock option inducement awards to newly hired employees. |
| 2026-02-26 | Earnings and pipeline | Positive | +9.1% | Strong 2025 revenue growth, narrower net loss, and pipeline progress. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent corporate/housekeeping news (board changes, conferences, inducement grants) often coincided with flat-to-negative next-day moves, while fundamental earnings news saw a positive reaction.
Over recent months, Akebia news has centered on corporate development, investor outreach, and fundamentals. A board refresh on Apr 1, 2026 and inducement option grants on Feb 27, 2026 were followed by modest share declines. Conference and R&D Day announcements in March had limited impact. In contrast, Q4 and full‑year 2025 results on Feb 26, 2026 highlighted revenue growth and a sharply narrower net loss, with the stock rising 9.09%. Today’s investor-meeting notice fits the non-fundamental communication pattern.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, Erik Ostrowski, Chief Financial and Chief Business Officer, and Dr. Steven Burke, Chief Medical Officer, will participate in one-on-one meetings at the Raymond James 2026 Biotech Innovation Symposium on Tuesday, April 14 in New York, NY. Company presentations are not planned at the Symposium.
During meetings, management will discuss its commercial products, and data and other information shared during Akebia’s recent R&D Day that showcased its robust pipeline of clinical stage kidney disease programs.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
